Telix Submits NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submi...
Source: businessinsider.com
Page 4 - Accessed May News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Accessed May Today - Breaking & Trending Today
New Research: Revealing the True Duration of Binge-Eating Disorder
Investigators at McLean Hospital found 61% and 45% of individuals still experiencing binge-eating disorder after 2.5 and 5 years after their initial diagnoses, respectively.
Source: psychiatrictimes.com
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous nonsmall cell lung cancer in TROPIONLung01 Phase III trial
Highlevel overall survival OS results from the TROPIONLung01 Phase III trial which previously met the dual primary endpoint of progressionfree survival PFS numerically favoured datopotamab deruxtecan DatoDXd compared to docetaxel in the overall trial population of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC treated with at least one prior line of therapy.
Source: businesswireindia.com
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Source: prnewswire.com
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%...
Source: prnewswire.com